Skip to content

For the treatment of all stages of neurotrophic keratitis (NK)

Prescribing Information
OXERVATE® (cenegermin-bkbj ophthalmic solution) 0.002% (20 mcg/mL) Resolutionary Care logo
hcp-oxe-hero-gradient patients hero lens concave
CONNECT to Care spelled out in liquid
Dompé CONNECT to Care

Access support and more through a single point of contact

Dompé CONNECT to Care logo

Providing practices and patients with assistance every step of the way

Checklist icon

Program enrollment

Shield with checkmark icon

Benefits verification

Clipboard with thumbs up icon

Prior authorizations

Cupped hand with coin icon

Patient financial assistance

Delivery van icon

Delivery coordination
& confirmation

Question mark in chat bubble icon

General questions

Since approval in 2018, more than 2000 total ophthalmologists and optometrists have prescribed OXERVATE®1

Patient Enrollment

How to enroll a patient

Submit a Patient Enrollment Form

A completed enrollment form serves as the OXERVATE® prescription and enrolls the patient into Dompé CONNECT to Care.

1

Fax completed enrollment form
on the patient’s behalf.

DOWNLOAD FORM
OR
2

Use the iAssist digital portal
to complete enrollment.

GO TO iASSIST

Remember: Patient Authorization section of enrollment form must be completed.

Questions? Contact Dompé CONNECT to Care

Phone 1-877-422-4412
Fax 1-855-263-1775

The majority of patients with commercial insurance may pay <$100 for an 8-week course of OXERVATE therapy

signup background gradient

Sign up for additional resources and to stay up to date about OXERVATE®

For US healthcare professionals only.

Important Safety Information

WARNINGS AND PRECAUTIONS

Use with Contact Lens
Contact lenses should be removed before applying OXERVATE because the presence of a contact lens (either therapeutic or corrective) could theoretically limit the distribution of cenegermin-bkbj onto the area of the corneal lesion. Lenses may be reinserted 15 minutes after administration.

Eye Discomfort
OXERVATE may cause mild to moderate eye discomfort such as eye pain during treatment. The patient should be advised to contact their doctor if a more serious eye reaction occurs.

ADVERSE REACTIONS

In clinical trials, the most common adverse reaction was eye pain following instillation which was reported in approximately 16% of patients. Other adverse reactions occurring in 1% to 10% of OXERVATE patients and more frequently than in the vehicle-treated patients included corneal deposits, foreign body sensation, ocular hyperemia, ocular inflammation and tearing.

USE IN SPECIFIC POPULATIONS

Pregnancy
There are no data from the use of OXERVATE in pregnant women to inform any drug associated risks.

Lactation
The developmental and health benefits of breastfeeding should be considered, along with the mother’s clinical need for OXERVATE, and any potential adverse effects on the breastfed infant from OXERVATE.

Pediatric Use
The safety and effectiveness of OXERVATE have been established in the pediatric population. Use of OXERVATE in pediatric patients 2 years of age and older is supported by evidence from adequate and well-controlled trials of OXERVATE in adults with additional safety data in children.

INDICATION

OXERVATE® (cenegermin-bkbj) ophthalmic solution 0.002% (20 mcg/mL) is indicated for the treatment of neurotrophic keratitis.

DOSAGE AND ADMINISTRATION

Instill one drop of OXERVATE in the affected eye(s), 6 times a day at 2-hour intervals for eight weeks.

To report ADVERSE REACTIONS, contact Dompé U.S. Inc. at 1-833-366-7387 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see full Prescribing Information for OXERVATE.

Reference: 1 . Data on File. Dompé U.S. Inc.; 2022.